Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Conditions: Advanced Malignant Solid Neoplasm; ARAF Gene Mutation; BRAF Gene Mutation; GNA11 Gene Mutation; GNAQ Gene Mutation; HRAS Gene Mutation; KRAS Gene Mutation; MAP2K1 Gene Mutation; MAPK1 Gene Mutation; NF1 Gene Mutation; NRAS Gene Mutation; Re current Ependymal Tumor; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Central Nervous System Neoplasm; Recurrent Malignant Germ Cell Tumor; ...
Source: ClinicalTrials.gov - October 8, 2018 Category: Research Source Type: clinical trials
